FDA Selects Fate Therapeutics for Key Manufacturing Readiness Pilot Program for FT819
FATE has more than doubled off its 52-week low of $0.91 on elevated volume (5.3× avg).
Summary
Fate Therapeutics has been selected by the U.S. FDA for its Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program for its investigational cell therapy, FT819. This program aims to support the manufacturing readiness of FT819, which previously received Regenerative Medicine Advanced Therapy (RMAT) designation according to the company's last 10-K. This selection is a significant positive development, indicating close FDA collaboration and support for the manufacturing pathway of a key pipeline asset. It de-risks the future commercialization process by ensuring early alignment with FDA manufacturing standards, potentially accelerating its path to market. Investors will watch for further updates on FT819's clinical development and manufacturing progress.
At the time of this announcement, FATE was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $0.91 to $1.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.